Literature DB >> 20695521

Enhanced generation of cytotoxic T lymphocytes by heat shock protein 70 fusion proteins harboring both CD8(+) T cell and CD4(+) T cell epitopes.

Seiji Takemoto1, Makiya Nishikawa, Xin Guan, Yuji Ohno, Tomoya Yata, Yoshinobu Takakura.   

Abstract

Heat shock protein 70 (Hsp70) can be a potent carrier of antigens because it is effectively delivered to antigen presenting cells (APCs) and activates innate immunity. To induce a potent cytotoxic T lymphocyte (CTL) response, a Hsp70 fusion protein harboring both CD8(+) and CD4(+) T cell epitopes was developed based on the recent understanding of the importance of the role of CD4(+) T cells in inducing the CTL response following vaccination. OVA(257-264) (pepI) and OVA(323-339) (pepII) were selected as the CD8(+) and CD4(+) T cell epitope of a model antigen, ovalbumin (OVA), respectively. Hsp70 and its fusion proteins, Hsp70-pepI, pepII-Hsp70, Hsp70-pepII and pepII-Hsp70-pepI, were developed. pepII-Hsp70 and pepII-Hsp70-pepI were effectively presented on MHC class II of macrophages compared with Hsp70-pepII, suggesting that pepII conjugation to the N-terminus of Hsp70 is better than the C-terminus for more effective MHC class II antigen presentation. Immunization with pepII-Hsp70-pepI resulted in a higher CTL activity than immunization with the mixture of Hsp70-pepI and pepII-Hsp70. Furthermore, pepII-Hsp70-pepI exhibited a greater antitumor effect in the mice bearing EG7 tumor cells than the physical mixture of Hsp70-pepI and pepII-Hsp70. In addition, immunization with the DCs pulsed with the fusion proteins also suggested that APCs which present both pepI and pepII can induce the highest CTL generation. These results demonstrated that Hsp70 fusion protein harboring both pepI and pepII is a useful option for Hsp70-based antigen delivery systems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695521     DOI: 10.1021/mp1001069

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  5 in total

1.  Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

Authors:  Candy S Hwang; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2018-11-20       Impact factor: 3.641

Review 2.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

3.  Malaria DNA vaccine gp96NTD-CSP elicits both CSP-specific antibody and CD8(+) T cell response.

Authors:  Zhangping Tan; TaoLi Zhou; Hong Zheng; Yan Ding; Wenyue Xu
Journal:  Parasitol Res       Date:  2015-03-20       Impact factor: 2.289

Review 4.  Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer.

Authors:  Maxim Shevtsov; Gabriele Multhoff
Journal:  Front Immunol       Date:  2016-04-29       Impact factor: 7.561

Review 5.  Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.

Authors:  Alexey V Baldin; Lyudmila V Savvateeva; Alexandr V Bazhin; Andrey A Zamyatnin
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.